Patent · US Active

Use of Flibanserin in the treatment of obesity

US10874668B2 · kind B2 · utility

0Cited by

60References

20Claims

0Family size

Assignee

Sprout Pharmaceuticals, Inc. · US

Inventors

Angelo Ceci · Mittelbiberach, DE
Marcus Schindler · Schwäbisch Hall, DE

Key dates

Filing date	Jun 3, 2019
Grant date	Dec 29, 2020
Priority date	—
Expiry date	Jun 3, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/335
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.